权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

PROTECT: optima4BP 2.0: prediction of Optimal Treatment and Route to achieve and maintain BP Target

保护：optima4BP 2.0：预测最佳治疗和路线以实现和维持血压目标

基本信息

批准号：
9901106
负责人：
Gabriela Voskerician
金额：
$ 75.02万
依托单位：
OPTIMA INTEGRATED HEALTH, INC.
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-05-01 至 2022-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9901106
关键词：
Acute Adverse drug event Adverse event Antihypertensive Agents Artificial Intelligence Blood Pressure California Cessation of life Clinical Clinical Trials Confidential Information Data Development Diabetes Mellitus Diagnosis Drug Combinations Enrollment Euclidean Space Exclusion Foundations Gender Generations Goals Guidelines Health Heart failure Hypertension Incidence Individual Intervention Intervention Trial Learning Life Lipids Logic Medical center Mind Modeling Modification Myocardial Infarction Names Nature Nurses Outcome Patients Performance Pharmaceutical Preparations Pharmacists Pharmacological Treatment Pharmacotherapy Phase Physicians Preparation Process Protocols documentation Resources Route Safety San Francisco Seminal Source Standardization Stroke Testing Time Training Universities Visit Women&apos s Health Women&apos s Role Work base blood pressure intervention cardiovascular risk factor clinical care clinically relevant commercial application comparative efficacy data mining data quality hypertension treatment innovation optimal treatments patient population prevent processing speed response stroke incidence stroke risk success

项目摘要

Need. In the US, 40 million patients with hypertension (HTN) have their blood pressure (BP) uncontrolled. BP above clinical Target even for a few months increases the risk for stroke (35-40%), heart failure (HF) (up to 64%), myocardial infarction (MI) (15-25%). Physician-nurse-pharmacist resource-intensive demonstrations in achieving & maintaining BP Target have shown promising results, but their real-life deployment was found unsustainable long-term. As a result, a process-standardized and sustainable solution is acutely needed. Solution. In response to this need, Optima Integrated Health developed optima4BP 1.0. It is a first-in-class artificial intelligence (AI) that simulates the process of clinical reasoning undertaken by the treating physician in optimizing the anti-HTN treatment towards BP Target. Just like the physician, optima4BP 1.0 cannot determine upfront the needed Optimal Treatment (OT) to achieve & maintain BP Target for 1-2 years. PROTECT [optima4BP 2.0: prediction of Optimal Treatment and route to achieve and maintain BP Target] proposes to establish upfront the personalized OT. The OT can then be used to select the shortest and safest treatment modification route needed to achieve & maintain BP Target. Phase II Goal. Build optima4BP 2.0. Phase I. Phase I Prior Work demonstrated that k-Nearest Neighbor (kNN), an AI model, can predict with ≥ 80% confidence the correct anti-HTN treatment, when compared to physician decision. Phase II. optima4BP 2.0 will predict the Optimal Treatment and route to achieve & maintain BP Target. Optimal Treatment data-mining source. PROTECT will use the SPRINT (Systolic Blood Pressure Intervention Trial, 2015) and ACCORD (Action to Control Cardiovascular Risk in Diabetes, 2010) clinical trial data. They represent the foundation of the most current anti-HTN treatment management national guidelines. Aim 1. Build kNN. Hypothesis. kNN can predict the proximity (clinical relevance) of a patient to an Optimal Treatment (OT). Milestone. Achieve ≥ 90% accuracy of prediction to physician decision. Phase I Data Preparation protocol will be applied to the SPRINT & ACCORD data. Then, the kNN Ensemble Learning function will be built to select the Optimal Treatment with the highest demonstrated efficacy by comparing the choice from 3 computational approaches developed and tested during Phase I. Aim 2. Build the Optimal Treatment Route (OTR). Hypothesis. Knowing the Current and Optimal Treatment (OT), an OTR can be built. Milestone. Safest Route: Achieve 100% exclusion of treatments that led to an adverse event in similar patient populations. Shortest Route: Achieve ≥30% reduction in number of treatment changes compared to physician route. The OTR will be built by comparing at each Step on the Route how similar each Candidate Treatment is to the OT through a computed similarity assessment. optima4BP 2.0 aims to establish a process-standardized & sustainable solution with the goal of reducing the incidence of stroke, HF, MI and death resulting from uncontrolled hypertension.

需要的在美国，4000万高血压（HTN）患者的血压（BP）不受控制。血压高于临床目标甚至几个月也会增加中风（35-40%）、心力衰竭（HF）（高达心肌梗死（MI）（15-25%）。医生-护士-药剂师资源密集型示范，实现和保持BP目标已经显示出有希望的结果，但他们的实际部署被发现不可持续的长期。因此，迫切需要一个流程标准化和可持续的解决方案。溶液为了满足这一需求，Optima Integrated Health开发了optima 4 BP 1.0。这是一流的人工智能（AI），模拟治疗医生进行的临床推理过程，针对BP目标优化抗HTN治疗。就像医生一样，optima 4 BP 1.0无法确定预先提供所需的最佳治疗（OT），以达到并维持BP目标1-2年。保护 [optima 4 BP 2.0：预测达到和维持BP目标的最佳治疗和途径]建议建立个性化的OT。OT可以用来选择最短和最安全的治疗方法为达到和保持BP目标而需要的路线修改。第二阶段目标。构建optima 4 BP 2.0。一阶段第一阶段的前期工作表明，k-最近邻（kNN），一种AI模型，可以预测≥ 与医生决定相比，正确的抗HTN治疗的置信度为80%。第二阶段。optima 4 BP 2.0将预测最佳治疗和路线，以达到和维持BP目标。最佳治疗数据挖掘源程序。CIMT将使用SPRINT（全身血压干预试验，2015年）和雅阁（控制糖尿病心血管风险行动，2010年）临床试验数据它们代表了最新的抗HTN治疗管理国家指南的基础。目标1。构建kNN。假说. kNN可以预测患者与最佳患者的接近度（临床相关性）。治疗（OT）。里程碑达到≥ 90%的医生决策预测准确度。I期数据准备方案将应用于SPRINT &雅阁数据。然后，kNN包围学习将建立一个函数，通过比较从第一阶段开发和测试的3种计算方法中选择。目标2.建立最佳治疗途径（OTR）。假说.了解当前和最佳治疗（OT），可以建立一个OTR。里程碑最安全的途径：实现100%排除导致类似患者人群中的不良事件。最短路径：减少≥30%的与医生途径相比，治疗发生了变化。OTR将通过比较通过计算的相似性评估确定每个候选治疗与OT的相似程度。 optima 4 BP 2.0旨在建立一个流程标准化和可持续的解决方案，目标是降低中风、HF、MI和不受控制的高血压导致的死亡的发生率。